Stefan den Hoedt, Felice E.E. van Veen, Jeroen R. Scheepe, Bertil F.M. Blok
To evaluate the safety and effectiveness of bladder irrigation (BI) with tap water to reduce antibiotic use for the treatment of urinary tract infections (UTIs) in patients with recurrent UTI symptoms and to assess the treatment satisfaction of BI.
目的：评估用自来水进行膀胱冲洗（BI）以减少抗生素使用的安全性和有效性，从而治疗反复出现尿路感染（UTI）症状的患者，并评估 BI 的治疗满意度。
{"title":"Bladder irrigation with tap water to reduce antibiotic use for urinary tract infections in catheter users","authors":"Stefan den Hoedt, Felice E.E. van Veen, Jeroen R. Scheepe, Bertil F.M. Blok","doi":"10.1111/bju.16552","DOIUrl":"https://doi.org/10.1111/bju.16552","url":null,"abstract":"To evaluate the safety and effectiveness of bladder irrigation (BI) with tap water to reduce antibiotic use for the treatment of urinary tract infections (UTIs) in patients with recurrent UTI symptoms and to assess the treatment satisfaction of BI.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142444247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Reuben Ben-David, Sarah Lidagoster, Jack Geduldig, Kaushik P. Kolanukuduru, Yuval Elkun, Neeraja Tillu, Asher Mandel, Mohammed Almoflihi, Basil Kaufmann, Kyrollis Attalla, Reza Mehrazin, Peter Wiklund, John P. Sfakianos
To assess recurrence-free survival (RFS) in patients with undetectable tumour-informed circulating tumour DNA (ctDNA) before radical cystectomy (RC) and evaluate if those who converted from detectable to undetectable ctDNA status after RC have similar RFS outcomes as those with persistently undetectable ctDNA status.
{"title":"Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes","authors":"Reuben Ben-David, Sarah Lidagoster, Jack Geduldig, Kaushik P. Kolanukuduru, Yuval Elkun, Neeraja Tillu, Asher Mandel, Mohammed Almoflihi, Basil Kaufmann, Kyrollis Attalla, Reza Mehrazin, Peter Wiklund, John P. Sfakianos","doi":"10.1111/bju.16556","DOIUrl":"https://doi.org/10.1111/bju.16556","url":null,"abstract":"To assess recurrence-free survival (RFS) in patients with undetectable tumour-informed circulating tumour DNA (ctDNA) before radical cystectomy (RC) and evaluate if those who converted from detectable to undetectable ctDNA status after RC have similar RFS outcomes as those with persistently undetectable ctDNA status.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142444246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zen Yang Ang, Yuke-Lin Kong, Zarith Nameyrra Md Nesran, Shaun Wen Huey Lee
To review and compare the efficacy of different delivery modes of decision aids (DAs), including computer-based, print-based, multimedia-based, video-based, and website-based on decision-making outcomes for prostate cancer screening compared to usual care (UC) and among the delivery modes.
{"title":"Efficacy of decision aid delivery modes in prostate cancer screening: umbrella review and network meta-analysis","authors":"Zen Yang Ang, Yuke-Lin Kong, Zarith Nameyrra Md Nesran, Shaun Wen Huey Lee","doi":"10.1111/bju.16545","DOIUrl":"https://doi.org/10.1111/bju.16545","url":null,"abstract":"To review and compare the efficacy of different delivery modes of decision aids (DAs), including computer-based, print-based, multimedia-based, video-based, and website-based on decision-making outcomes for prostate cancer screening compared to usual care (UC) and among the delivery modes.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142436389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesco Del Giudice, Annarita Vestri, Danilo Alunni Fegatelli, Tanja Hüsch, Jonathan Belsey, Rajesh Nair, Eila C. Skinner, Benjamin I. Chung, Martina Pecoraro, Alessandro Sciarra, Giorgio Franco, Benjamin Pradere, Paola Gazzaniga, Fabio Massimo Magloicca, Valeria Panebianco, Ettore De Berardinis
BackgroundA second transurethral resection of bladder tumour (Re‐TURBT) is recommended by European Association of Urology (EAU) Guidelines on non‐muscle‐invasive bladder cancers (NMIBCs) due to the risk of understaging and/or persistent disease following the primary resection. However, in many cases this may be unnecessary, potentially harmful, and significantly expensive constituting overtreatment. The CUT‐less trial aims to combine the preoperative staging accuracy of Vesical Imaging‐Reporting and Data System (VI‐RADS) and the intraoperative enhanced ability of photodynamic diagnosis (PDD) to overcome the primary TURBT pitfalls thus potentially re‐defining criteria for Re‐TURBT indications.Study DesignSingle‐centre, non‐inferiority, phase IV, open‐label, randomised controlled trial with 1:1 ratio.EndpointsThe primary endpoint is short‐term BC recurrence between the study arms to assess whether patients preoperatively categorised as VI‐RADS Score 1 and/or Score 2 (i.e., very‐low and low likelihood of MIBC) could safely avoid Re‐TURBT by undergoing primary PDD‐TURBT. Secondary endpoints include mid‐ and long‐term BC recurrences and progression (i–ii). Also, health‐related quality of life (HRQoL) outcomes (iii) and health‐economic cost–benefit analysis (iv) will be performed.Patients and MethodsAll patients will undergo preoperative Multiparametric Magnetic Resonance Imaging of the bladder with VI‐RADS score determination. A total of 327 patients with intermediate‐/high‐risk NMIBCs, candidate for Re‐TURBT according to EAU Guidelines, will be enrolled over a 3‐year period. Participants will be randomised (1:1 ratio) to either standard of care (SoC), comprising primary white‐light (WL) TURBT followed by second WL Re‐TURBT; or the Experimental arm, comprising primary PDD‐TURBT and omitting Re‐TURBT. Both groups will receive adjuvant intravesical therapy and surveillance according to risk‐adjusted schedules. Measure of the primary outcome will be the relative proportion of BC recurrences between the SoC and Experimental arms within 4.5 months (i.e., any ‘early’ recurrence detected at first follow‐up cystoscopy). Secondary outcomes measures will be the relative proportion of late BC recurrences and/or BC progression detected after 4.5 months follow‐up. Additionally, we will compute the HRQoL variation from NMIBC questionnaires modelled over a patient lifetime horizon and the health‐economic analyses including a short‐term cost–benefit assessment of incremental costs per Re‐TURBT avoided and a longer‐term cost‐utility per quality‐adjusted life year gained using 2‐year clinical outcomes to drive a lifetime model across the two arms of treatment.Trial RegistrationClinicalTrial.gov identifier (ID): NCT05962541; European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) ID: 2023‐507307‐64‐00.
背景欧洲泌尿外科协会（EAU）关于非肌层浸润性膀胱癌（NMIBCs）的指南建议进行第二次经尿道膀胱肿瘤切除术（Re-TURBT），因为初次切除术后可能会出现分期不足和/或疾病持续存在的风险。然而，在很多情况下，这可能是不必要的、潜在有害的，而且费用高昂，构成过度治疗。CUT-less试验旨在将膀胱造影报告和数据系统（VI-RADS）的术前分期准确性与光动力诊断（PDD）的术中增强能力相结合，克服原发性TURBT的缺陷，从而有可能重新定义Re-TURBT的适应症标准。研究设计单中心、非劣效、IV 期、开放标签、随机对照试验，比例为 1:1。终点主要终点是研究臂之间的短期 BC 复发率，以评估术前被归类为 VI-RADS 评分 1 和/或评分 2（即：极低和低心肌梗死可能性）的患者是否复发、或评分 2（即发生 MIBC 的可能性很低和很低）的患者是否可以通过接受初级 PDD-TURBT 术安全地避免再次 TURBT。次要终点包括 BC 的中长期复发和进展（i-ii）。此外，还将进行健康相关生活质量（HRQoL）结果(iii)和健康经济成本效益分析(iv)。患者和方法所有患者将在术前接受膀胱多参数磁共振成像，并进行VI-RADS评分。根据 EAU 指南，共有 327 名中/高危 NMIBC 患者将在 3 年内接受 Re-TURBT 治疗。参试者将按 1:1 的比例随机分配到标准护理组（SoC），包括初级白光 (WL) TURBT，然后进行第二次 WL Re-TURBT；或实验组，包括初级 PDD-TURBT，省略 Re-TURBT。两组患者都将根据风险调整后的计划接受膀胱内辅助治疗和监测。衡量主要结果的指标是 SoC 组和实验组在 4.5 个月内 BC 复发的相对比例（即首次随访膀胱镜检查时发现的任何 "早期 "复发）。次要结局指标将是随访 4.5 个月后发现的晚期 BC 复发和/或 BC 进展的相对比例。此外，我们还将计算NMIBC问卷的HRQoL变化，并在患者的终生范围内进行建模。健康经济分析包括短期成本效益评估，即每避免一次Re-TURBT的增量成本，以及长期成本效用，即每获得一个质量调整生命年，使用2年的临床结果来驱动两个治疗臂的终生模型：NCT05962541; European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) ID: 2023-507307-64-00。
{"title":"VI‐RADS followed by Photodynamic Transurethral Resection of Non‐Muscle‐Invasive Bladder Cancer vs White‐Light Conventional and Second‐resection: the ‘CUT‐less’ Randomised Trial Protocol","authors":"Francesco Del Giudice, Annarita Vestri, Danilo Alunni Fegatelli, Tanja Hüsch, Jonathan Belsey, Rajesh Nair, Eila C. Skinner, Benjamin I. Chung, Martina Pecoraro, Alessandro Sciarra, Giorgio Franco, Benjamin Pradere, Paola Gazzaniga, Fabio Massimo Magloicca, Valeria Panebianco, Ettore De Berardinis","doi":"10.1111/bju.16531","DOIUrl":"https://doi.org/10.1111/bju.16531","url":null,"abstract":"BackgroundA second transurethral resection of bladder tumour (Re‐TURBT) is recommended by European Association of Urology (EAU) Guidelines on non‐muscle‐invasive bladder cancers (NMIBCs) due to the risk of understaging and/or persistent disease following the primary resection. However, in many cases this may be unnecessary, potentially harmful, and significantly expensive constituting overtreatment. The CUT‐<jats:italic>less</jats:italic> trial aims to combine the preoperative staging accuracy of Vesical Imaging‐Reporting and Data System (VI‐RADS) and the intraoperative enhanced ability of photodynamic diagnosis (PDD) to overcome the primary TURBT pitfalls thus potentially re‐defining criteria for Re‐TURBT indications.Study DesignSingle‐centre, non‐inferiority, phase IV, open‐label, randomised controlled trial with 1:1 ratio.EndpointsThe primary endpoint is short‐term BC recurrence between the study arms to assess whether patients preoperatively categorised as VI‐RADS Score 1 and/or Score 2 (i.e., very‐low and low likelihood of MIBC) could safely avoid Re‐TURBT by undergoing primary PDD‐TURBT. Secondary endpoints include mid‐ and long‐term BC recurrences and progression (i–ii). Also, health‐related quality of life (HRQoL) outcomes (iii) and health‐economic cost–benefit analysis (iv) will be performed.Patients and MethodsAll patients will undergo preoperative Multiparametric Magnetic Resonance Imaging of the bladder with VI‐RADS score determination. A total of 327 patients with intermediate‐/high‐risk NMIBCs, candidate for Re‐TURBT according to EAU Guidelines, will be enrolled over a 3‐year period. Participants will be randomised (1:1 ratio) to either standard of care (SoC), comprising primary white‐light (WL) TURBT followed by second WL Re‐TURBT; or the Experimental arm, comprising primary PDD‐TURBT and omitting Re‐TURBT. Both groups will receive adjuvant intravesical therapy and surveillance according to risk‐adjusted schedules. Measure of the primary outcome will be the relative proportion of BC recurrences between the SoC and Experimental arms within 4.5 months (i.e., any ‘early’ recurrence detected at first follow‐up cystoscopy). Secondary outcomes measures will be the relative proportion of late BC recurrences and/or BC progression detected after 4.5 months follow‐up. Additionally, we will compute the HRQoL variation from NMIBC questionnaires modelled over a patient lifetime horizon and the health‐economic analyses including a short‐term cost–benefit assessment of incremental costs per Re‐TURBT avoided and a longer‐term cost‐utility per quality‐adjusted life year gained using 2‐year clinical outcomes to drive a lifetime model across the two arms of treatment.Trial Registration<jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"http://clinicaltrial.gov\">ClinicalTrial.gov</jats:ext-link> identifier (ID): NCT05962541; European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) ID: 2023‐507307‐64‐00.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142431223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Arran Dingwall, James Leighton, Angus Luk, Mark Chambers, Bhaskar Somani, Robert Geraghty
To investigate the outcomes of ureteroscopy and lasertripsy in lower pole renal stones <2 cm when treated in situ compared to displacement to the upper pole.
研究输尿管镜检查和激光碎石术对下极肾结石<2 cm原位治疗与上极肾结石移位治疗的效果。
{"title":"Ureteroscopy and lasertripsy for lower pole stones <2 cm, in situ vs displacement? A systematic review and meta-analysis","authors":"Arran Dingwall, James Leighton, Angus Luk, Mark Chambers, Bhaskar Somani, Robert Geraghty","doi":"10.1111/bju.16534","DOIUrl":"https://doi.org/10.1111/bju.16534","url":null,"abstract":"To investigate the outcomes of ureteroscopy and lasertripsy in lower pole renal stones <2 cm when treated <i>in situ</i> compared to displacement to the upper pole.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142431731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Patrick Ngo, Nariman Ahmadi, Peter Ferguson, Ciara Conduit, Sophie O'Haire, Anna Kuchel, Ganes Pranavan, Andrew Weickhardt, Ben Tran, Peter Grimison
{"title":"Characteristics and outcomes among patients with delayed orchidectomy for advanced germ cell tumours.","authors":"Patrick Ngo, Nariman Ahmadi, Peter Ferguson, Ciara Conduit, Sophie O'Haire, Anna Kuchel, Ganes Pranavan, Andrew Weickhardt, Ben Tran, Peter Grimison","doi":"10.1111/bju.16546","DOIUrl":"https://doi.org/10.1111/bju.16546","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response to Lin et al. 'RE: urinary incontinence recovery and surgical techniques in endoscopic enucleation of the prostate'.","authors":"Shao-Wei Wu, Chi-Shin Tseng, Shi-Wei Huang","doi":"10.1111/bju.16555","DOIUrl":"https://doi.org/10.1111/bju.16555","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alon Lazarovich, Tanya W Kristof, Shavano Steadman, Aaron S Dahmen, Michelle A Josephson, Rolf Barth, Todd M Morgan, Marc-Olivier Timsit, Scott Eggener
Objective: To analyse the management and outcomes of individuals diagnosed with prostate cancer either before or after organ transplantation, as the impact of organ transplantation and associated immunosuppression on the incidence, progression, and mortality of prostate cancer remains an area of substantial clinical interest and uncertainty.
Patients and methods: We conducted a retrospective analysis of patients from two tertiary care centres who had solid organ transplantation and were diagnosed with prostate cancer before or after organ transplantation. Data collected included demographics and clinical information.
Results: The cohort consisted of 110 patients with a median (interquartile range [IQR]) age at prostate cancer diagnosis of 62 (56.6-67.2) years and a median (IQR) age at transplantation of 58.6 (52.7-65.3) years. Renal transplantation was the most common (54%). The median (IQR) prostate-specific antigen concentration at prostate cancer diagnosis was 6.2 (4.5-10) ng/mL, and the distribution of American Urological Association risk groups was: low risk, 36%; intermediate risk, 50%; and high risk, 14%. In all, 45 (41%) patients were diagnosed with prostate cancer prior to transplantation. Management included radical prostatectomy (RP; 62%), prostate radiotherapy (RT; 13%), and active surveillance (AS; 18%). During a median (IQR) follow-up of 5.8 (2.5-10) years from prostate cancer diagnosis, one (2%) patient developed metastatic disease. In all, 65 (59%) patients were diagnosed with prostate cancer subsequent to organ transplantation. Management included AS (29%), RT (45%), and RP (15%). During a median (IQR) follow-up of 5.3 (1-8.4) years, three patients (5%) developed metastatic disease. There were no deaths from prostate cancer.
Conclusion: A diagnosis of localised prostate cancer should not preclude solid organ transplantation, and the presence of a transplant does not appear to substantially impact risk of prostate cancer progression.
{"title":"Prostate cancer and solid organ transplantation: patient management and outcomes.","authors":"Alon Lazarovich, Tanya W Kristof, Shavano Steadman, Aaron S Dahmen, Michelle A Josephson, Rolf Barth, Todd M Morgan, Marc-Olivier Timsit, Scott Eggener","doi":"10.1111/bju.16558","DOIUrl":"https://doi.org/10.1111/bju.16558","url":null,"abstract":"<p><strong>Objective: </strong>To analyse the management and outcomes of individuals diagnosed with prostate cancer either before or after organ transplantation, as the impact of organ transplantation and associated immunosuppression on the incidence, progression, and mortality of prostate cancer remains an area of substantial clinical interest and uncertainty.</p><p><strong>Patients and methods: </strong>We conducted a retrospective analysis of patients from two tertiary care centres who had solid organ transplantation and were diagnosed with prostate cancer before or after organ transplantation. Data collected included demographics and clinical information.</p><p><strong>Results: </strong>The cohort consisted of 110 patients with a median (interquartile range [IQR]) age at prostate cancer diagnosis of 62 (56.6-67.2) years and a median (IQR) age at transplantation of 58.6 (52.7-65.3) years. Renal transplantation was the most common (54%). The median (IQR) prostate-specific antigen concentration at prostate cancer diagnosis was 6.2 (4.5-10) ng/mL, and the distribution of American Urological Association risk groups was: low risk, 36%; intermediate risk, 50%; and high risk, 14%. In all, 45 (41%) patients were diagnosed with prostate cancer prior to transplantation. Management included radical prostatectomy (RP; 62%), prostate radiotherapy (RT; 13%), and active surveillance (AS; 18%). During a median (IQR) follow-up of 5.8 (2.5-10) years from prostate cancer diagnosis, one (2%) patient developed metastatic disease. In all, 65 (59%) patients were diagnosed with prostate cancer subsequent to organ transplantation. Management included AS (29%), RT (45%), and RP (15%). During a median (IQR) follow-up of 5.3 (1-8.4) years, three patients (5%) developed metastatic disease. There were no deaths from prostate cancer.</p><p><strong>Conclusion: </strong>A diagnosis of localised prostate cancer should not preclude solid organ transplantation, and the presence of a transplant does not appear to substantially impact risk of prostate cancer progression.</p>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"RE: urinary incontinence recovery and surgical techniques in endoscopic enucleation of the prostate.","authors":"Yu-Hsiang Lin, Chih-Te Lin, Kuo-Jen Lin","doi":"10.1111/bju.16554","DOIUrl":"https://doi.org/10.1111/bju.16554","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：